Luciferase News and Research

RSS

Encouraging in vitro results with SARS-CoV-2-spike-specific polyclonal antibody fragments

In a recent study posted to the bioRxiv* preprint server, researchers demonstrated the potent neutralizing ability of a polyclonal equine antibody (Ab), FBR-002, against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs), including Omicron.

28 Feb 2022

Study suggests non-classical inhibition of TBK1/IKKε is protective against severe COVID-19 immunopathology in vivo

A study posted suggested the inhibition of TBK1 and its homolog KKε could decrease the severity of COVID-19.

21 Feb 2022

Study examines lyophilized mRNA-lipid nanoparticle vaccines with long-term stability

A new study explored the high immunogenicity and stability of lyophilized mRNA-LNP vaccines in relation to SARS-CoV-2.

16 Feb 2022

The in vitro selection of a remdesivir-resistant SARS-CoV-2 mutation

Researchers select and study an RDV-resistant virus by serial passaging of wild type SARS-CoV-2 in the presence of increasing concentrations of RDV.

15 Feb 2022

Antiviral activity assessment of remdesivir against 10 current and former SARS-CoV-2 variant clinical isolates

A new study published demonstrated the in vitro potencies of RDV and GS-441524 through PRA, and nucleoprotein ELISA against SARS-CoV-2 and other VOC/VOIs isolates with specific substitutions in Nsp12.

15 Feb 2022

Study shows expression of viral proteases may be used to quantitate SARS-CoV-2 infected cells

A new study describes a new method to quantify SARS-CoV-2 infection, which is much simpler and faster compared to existing methods.

14 Feb 2022

Study provides evidence for spike protein-independent attenuation of SARS-CoV-2 Omicron variant

A new study provided the structural basis for a robust interaction between the receptor-binding domain of the SARS-CoV-2 Omicron spike protein and mouse ACE2.

13 Feb 2022

Rapid generation and evaluation of an mRNA vaccine candidate specific to Omicron

A recent study demonstrated the development of a potential SARS-CoV-2 Omicron variant-specific mRNA vaccine candidate.

10 Feb 2022

Study compares the neutralizing potential of antibodies against two Omicron variants

A new study investigates if the two SARS-CoV-2 Omicron variants BA.1 and BA.2 are comparable with respect to their ability to evade the host immunity induced by vaccination or prior infection.

9 Feb 2022

SARS-CoV-2 virus co-opts intrinsic cellular machinery to suppress interferon production

In a recent study posted to the bioRxiv* preprint server, researchers evaluated the mechanism of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-associated inflammatory marker interferon (IFN) repression in hosts.

25 Jan 2022

Study shows SARS-CoV-2 prompts NLRP3 inflammasome activation through spike-ACE2 receptor interaction

New research assesses the NLR family pyrin domain containing 3 (NLRP3) inflammasome activation in response to SARS-CoV-2 and its spike protein, and the effects of this exposure in the presence of a-synuclein protein aggregate fibrils.

17 Jan 2022

Study demonstrates that intra-host SARS-CoV-2 variants with reduced infectivity are developed during infection

A new paper discusses the appearance of quasi-species in a single host with prolonged infection, with different rates of infectivity and sensitivity to neutralization by antibodies elicited by the Pfizer vaccine or those present in convalescent plasma.

17 Jan 2022

SARS-CoV-2 shown to spread through cell-to-cell transmission

A new study investigated SARS-CoV-2 cell-to-cell transmission in the context of cell-free infection and compared it to SARS-CoV.

10 Jan 2022

SARS-CoV-2 Delta sublineage AY.4.2 shows no increase in cell entry or antibody evasion

Researchers from Germany, in their recent study published in the journal Cellular & Molecular Immunology, have evaluated the mutations in the S protein of one such SARS-CoV-2 strain, a Delta sublineage AY.4.2, which is currently expanding in the UK, and have found that it neither contains any potential for increased cell entry nor antibody escape.

10 Jan 2022

Luciferase News and Research

Encouraging in vitro results with SARS-CoV-2-spike-specific polyclonal antibody fragments

Study suggests non-classical inhibition of TBK1/IKKε is protective against severe COVID-19 immunopathology in vivo

Study examines lyophilized mRNA-lipid nanoparticle vaccines with long-term stability

The in vitro selection of a remdesivir-resistant SARS-CoV-2 mutation

Antiviral activity assessment of remdesivir against 10 current and former SARS-CoV-2 variant clinical isolates

Study shows expression of viral proteases may be used to quantitate SARS-CoV-2 infected cells

Study provides evidence for spike protein-independent attenuation of SARS-CoV-2 Omicron variant

Rapid generation and evaluation of an mRNA vaccine candidate specific to Omicron

Study compares the neutralizing potential of antibodies against two Omicron variants

SARS-CoV-2 virus co-opts intrinsic cellular machinery to suppress interferon production

Study shows SARS-CoV-2 prompts NLRP3 inflammasome activation through spike-ACE2 receptor interaction

Study demonstrates that intra-host SARS-CoV-2 variants with reduced infectivity are developed during infection

SARS-CoV-2 shown to spread through cell-to-cell transmission

SARS-CoV-2 Delta sublineage AY.4.2 shows no increase in cell entry or antibody evasion

Small molecule identified as a SARS-CoV-2 inhibitor

Exploring vaccine-induced cellular immunity against SARS-CoV-2 Omicron variant

mRNA booster vaccine confers strong protection against SARS-CoV-2 Omicron in cancer patients

TriSb92 as a potential inhibitor against SARS-CoV-2 variants including Omicron

Nanoengineers develop a new approach to effectively deliver mRNA into cells

Monitoring cellular metabolism for NAFLD/NASH liver disease research

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News